Episodes
Friday Oct 13, 2017
Painting a New CANVAS for SGLT-2 Inhibitors?
Friday Oct 13, 2017
Friday Oct 13, 2017
While good glycemic control has been shown to prevent microvascular complications (e.g. retinopathy, nephropathy, neuropathy), only a few anti-diabetic agents have been shown to reduce macrovascular complications (e.g. cardiovascular events. Empagliflozin, a sodium glucose transporter-2 (SGLT2) inhibitor, not only reduced the risk of CV events but also all-cause mortality in the EMPA-REG OUTCOME study. Based on this data, the SGLT2 inhibitors were given favorable second-line treatment status in the most recent AACE/ACE clinical practice guidelines. But do all SGLT2 inhibitors confer the same benefits… and risks? The Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) trial assessed the cardiovascular and renal benefits from long-term canagliflozin use. The results are both reassuring and unexpected.
Guest Author: Sean Lasota, Pharm.D.
Music by Good Talk
Friday Sep 22, 2017
Friday Sep 22, 2017
According to the 2016 CHEST VTE Guidelines, at least 3 months of therapy is recommended for an unprovoked DVT or PE (Grade 1B). Thereafter, the clinician is expected to weigh the risks and benefits to determine if extended therapy is appropriate. Balancing the risk of mortality from recurrent VTE versus major bleeding has been challenging. A validated clinical decision tool is sorely needed! Until recently, no risk assessment tool has been validated and therefore none have been widely adopted in practice.
Guest Author: Carol Chan, Pharm.D.
Music by Good Talk
Friday Sep 08, 2017
Testing the Limits on Blood Glucose Monitoring: Can We Safely Cut Back?
Friday Sep 08, 2017
Friday Sep 08, 2017
Is self-monitoring of blood glucose (SMBG) cost-effective? SMBG is often recommended to help guide treatment decisions. Consumer-oriented advertising often promotes frequent SMBG as means to achieve better glycemic control but current clinical practice guidelines do not provide specific recommendations regarding the frequency of blood glucose monitoring. The lack of conclusive evidence supporting the clinical benefits of routine SMBG combined with the rising costs of healthcare has led some payers to place limits on SMBG testing supplies. Is this wise policy? Or does it lead to poor health outcomes?
Guest Authors: KyAnn Wisse, PharmD, BCACP and Dawn Fuke, Pharm.D, BCPS
Music by Good Talk
Friday Aug 25, 2017
Friday Aug 25, 2017
Statins reduce atherosclerotic cardiovascular disease (ASCVD) risk. However, the utility of statin therapy in older adults — particularly in those age 75 years and older — remains controversial. The need for additional evidence to guide clinical practice is underscored by the fact that one-in-three older Americans report taking a statin. Given the paucity of prospective data, a post-hoc analysis of the ALLHAT-LLT (Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial - Lipid Lowering Trial) was recently published. Does this new analysis really help inform the decision?
Guest Author: Leo Buckley, Pharm.D.
Music by Good Talk
Friday Aug 11, 2017
Wrapping up Knee Pain: Cabbage Leaf Wraps for Osteoarthritis of the Knee
Friday Aug 11, 2017
Friday Aug 11, 2017
Cabbage leaf wraps (CLWs) … the newest health craze trending on social media? A culinary masterpiece? Or an effective complementary treatment for osteoarthritis (OA) relief? A recently published study attempted to answer the latter question.
Guest Author: Emily Prohaska, PharmD, BCACP, BCGP
Music by Good Talk
Thursday Jul 27, 2017
All for One and FOURIER for All!
Thursday Jul 27, 2017
Thursday Jul 27, 2017
Although statins have a proven benefit and are widely used, ASCVD continues to be the leading cause of death in the US. In 2015, two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab (Praluent®) and evolocumab (Repatha®), were approved to treat elevated cholesterol when added to maximally-tolerated statin therapy in patients with familial hypercholesterolemia or history of ASCVD. However, the lack of long-term CV outcomes data, high cost, and uncertainty regarding place in therapy have limited their wide-spread use. The recently published FOURIER Study provides compelling new evidence.
Guest Author: Kelly Starman, Pharm.D., BCPS
Theme music by Good Talk.
Monday Jun 26, 2017
Monday Jun 26, 2017
Observational studies and systematic reviews have shown an association between low vitamin D concentrations and acute respiratory tract infections (ARTIs). An association is one thing, but can vitamin D supplementation reduce the risk of ARTIs? That’s what a recent systematic review and meta-analysis attempted to determine.
Guest Author: Amanda Schartel, Pharm.D., BCACP
Theme music by Good Talk
Saturday Jun 10, 2017
Saturday Jun 10, 2017
For the acute treatment of venous thromboembolism, the direct oral anticoagulants (DOACs) have increasingly replaced injectable anticoagulant therapy followed by warfarin. For patients with an unprovoked deep vein thrombosis or pulmonary embolism who may benefit from long-term extended prophylaxis for the secondary prevention of VTE, the choice is less clear. Should a DOAC be used? If so, which one and what's the best dose? What about low-dose aspirin? Is extended therapy needed at all? The EINSTEIN CHOICE study adds important new insights to the growing body of literature.
Guest Author: Sarah Anderson, PharmD, BCPS
Theme music by Good Talk
Friday Apr 14, 2017
Peeling Back the Layers on Coated Aspirin
Friday Apr 14, 2017
Friday Apr 14, 2017
More than 15 million Americans have coronary heart disease and most should be taking aspirin daily. Given aspirin’s ubiquity in cardiovascular medicine and patients’ pill boxes, it is shocking that there are still so many unanswered questions about aspirin use. Which dose and dosage forms should be prescribed? How common is aspirin resistance? What is the relationship between platelet inhibition and clinical outcomes?
Guest Author: Daniela Valencia, Pharm.D.
Theme Music by Good Talk
Friday Mar 24, 2017
Friday Mar 24, 2017
Many patients with atrial fibrillation (AF) received triple antithrombotic therapy after undergoing a percutaneous coronary intervention (PCI) and receiving cardiac stent. Triple therapy consists of warfarin plus dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and low-dose aspirin. But is triple therapy the best approach? This practice, while widely employed, is not entirely evidence-based. Moreover, the effectiveness and safety of the direct oral anticoagulants (DOACs) in this patient population is unknown.
Theme Music by Good Talk